| Application | Recommended Dilution |
|---|---|
| ELISA | 1:5000-1:50000 |
SLC2A1, commonly known as GLUT1, serves as the primary facilitated glucose transporter in erythrocytes and across the blood-brain barrier, making it essential for basal glucose uptake in numerous tissues. This transporter has garnered significant research attention due to its involvement in GLUT1 deficiency syndrome, various movement disorders including paroxysmal choreoathetosis, and its notable upregulation in many cancer types where altered glucose metabolism supports rapid cell proliferation. Additionally, SLC2A1 functions as a receptor for HTLV-1 and HTLV-2, expanding its relevance to viral pathogenesis research.
This recombinant monoclonal antibody, clone 18A8, offers researchers the reproducibility and consistency that recombinant technology provides. Unlike traditional hybridoma-derived antibodies, this sequence-defined reagent ensures identical performance across lots, eliminating batch-to-batch variability that can compromise longitudinal studies or multi-site collaborations. The antibody is produced with a human IgG1 framework and undergoes affinity chromatography purification, delivering a reliable reagent for demanding experimental workflows.
Functional validation demonstrates robust binding activity against human SLC2A1, with ELISA testing showing an EC50 range of 5.023 to 6.275 ng/mL when detecting immobilized recombinant human SLC2A1 protein. This high-affinity binding, confirmed against appropriate negative controls, supports confident target detection in ELISA applications at dilutions ranging from 1:5000 to 1:50000.
For investigators exploring glucose metabolism, cancer biology, neurological disorders, or signal transduction pathways, this antibody provides a dependable tool for quantitative detection of human SLC2A1 in immunoassay formats.
Email: support@cusabio.com
Distributors Worldwide